Company Overview of Trigemina, Inc.
Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.
809-B Cuesta Drive
Mountain View, CA 94040
Founded in 2006
Key Executives for Trigemina, Inc.
Trigemina, Inc. Key Developments
Similar Private Companies By Industry
|Functional Genetics, Inc.||United States|
|Targeted Molecules Corp.||United States|
|Selexagen Therapeutics, Inc.||United States|
|Pharmacia & Upjohn Company LLC||United States|
|Histogen, Inc.||United States|
Recent Private Companies Transactions
June 17, 2013
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Tampa, FL | Bristol-Myers SquibbPosted: Nov 13
- Detroit, MI | AstraZenecaPosted: Dec 09
- San Francisco, CA | JobvertisePosted: Nov 30
- Princeton, NJ | RGPPosted: Nov 27
Sponsored Financial Commentaries
To contact Trigemina, Inc., please visit trigemina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.